Chimerix, Inc

Short Term Long Term Short Term Comparison Long Term Comparison

CMRX
1d-4.80%
1w-7.62%
1m-20.47%
1y-23.78%
CMRX
1y-23.78%
5y-66.25%
10y-95.25%
20y0.00%

Bitcoin
-0.82%
-9.09%
-6.40%
106.24%
Bitcoin
106.24%
1,146.32%
11,770.30%
0.00%

Ethereum
-0.90%
-11.75%
-14.49%
45.57%
Ethereum
45.57%
1,828.08%
0.00%
0.00%

Gold
0.26%
2.56%
11.41%
20.52%
Gold
20.52%
88.92%
85.82%
499.35%

Silver
0.47%
4.25%
15.38%
14.30%
Silver
14.30%
94.94%
48.08%
306.93%

Apple
-2.19%
1.78%
0.04%
5.09%
Apple
5.09%
260.11%
-66.73%
39,041.00%

Amazon
-1.68%
-1.44%
4.92%
78.52%
Amazon
78.52%
96.45%
-43.46%
7,943.96%

Microsoft
-1.96%
-2.97%
-0.67%
45.75%
Microsoft
45.75%
259.81%
923.86%
2,532.12%

S&P 500
-1.20%
-2.84%
-1.08%
22.34%
S&P 500
22.34%
74.12%
171.80%
346.13%

Dow & Jones
-0.65%
-2.95%
-2.53%
11.36%
Dow & Jones
11.36%
42.65%
129.74%
261.03%

ATH

ATH Price$57.43
ATH Date2015-08-05
% since ATH-98.41%
% to ATH6,179.25%

ATL

ATL Price$0.90
ATL Date2023-11-13
% from ATL1.61%
Last Low Price$0.9001
Last Low Date2023-11-13
% From Last Low1.61%

IPO

IPO Price$15.14
% Current ROI USD-93.96%
ATH Price$57.43
% ROI ATH 638,040.22%

[addtoany]

Graph takes few seconds to load...

[financial_chart symbol="CMRX"]

Key Data [addtoany]

Current price	$0.9146
Sector	Healthcare
Industry	Biotechnology
Today's High/Low	$0.9699/$0.9012
Volume	506,323.00
Previous Close	$0.9607
52 Week High/Low	$1.57/$0.88
Market Cap	85,704,432.00
P/E Ratio	0
Forward P/E 1 Yr.	$1.21
Earnings Per Share(EPS)	$-0.96
Annualized Dividend	$0

$0.9146

[addtoany]

Chimerix, Inc., a development-stage biopharmaceutical company, focuses on accelerating the advancement of various medicines that impact in the lives of patients living with cancer and other serious diseases.
Its clinical stage development programs include brincidofovir (BCV), an antiviral drug candidate in development as a medical countermeasure for smallpox; dociparstat sodium (DSTAT), which inhibits the activities of key proteins implicated in the resistance of acute myeloid leukemia blasts and leukemic stem cells to chemotherapy; and ONC201 a program for potentially treating tumors which harbor the H3 K27M mutation in recurrent diffuse midline glioma patients.
The company has license agreements with Biomedical Advanced Research and Development Authority for the development of brincidofovir for use in the treatment of smallpox; Cantex Pharmaceuticals, Inc.
to develop and commercialize a glycosaminoglycan compound; and SymBio Pharmaceuticals to develop, manufacture, and commercialize BCV for various human indications. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.

Annual Data \| Millions of US $ except per share data	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31
Cash on hand	$113.48	$186.53	$151.52	$232.02	$220.33	-	-	-	-	-
Receivables	$1.23	$0.33	$1.68	$1.60	$3.10	$0.66	-	-	-	-
Inventory	-	-	$0	$0	$0	$0	$0	-	-	-
Pre-Paid Expenses	-	-	-	-	-	-	-	-	-	-
Other Current Assets	$3.39	$2.60	$3.33	$2.85	$5.40	$2.22	$2.79	$1.02	$1.11	-
Total Current Assets	$118.09	$189.46	$156.53	$236.47	$228.84	$237.46	$0	-	-	-
Property, Plant, And Equipment	$1.25	$1.21	$1.89	$2.84	$3.05	$1.31	$0.34	$0.41	$0.56	-
Long-Term Investments	-	$0	$76.73	$47.41	$124.04	$52.97	-	-	-	-
Goodwill And Intangible Assets	-	-	$0	$0	$0	$0	$0	-	-	-
Other Long-Term Assets	$0.03	$0.05	$0.07	$0.06	$0.07	$0.14	$0.04	$0.07	$0.05	-
Total Long-Term Assets	$1.28	$1.26	$78.70	$50.31	-	-	-	-	-	-
Total Assets	$119.38	$190.71	$235.23	$286.77	$355.99	$291.88	$113.39	$32.03	$25.43	-
Total Current Liabilities	$9.23	$12.97	$13.20	$10.11	$20.18	$17.07	$10.21	$7.62	$6.81	-
Long Term Debt	-	-	$0	$0	$0	$0	$4.29	$9.87	$2.44	-
Other Non-Current Liabilities	-	-	$0.22	$0.44	$0.35	$0.18	$0.35	$7.85	$6.49	-
Total Long Term Liabilities	$0.20	$0.14	$0.22	$0.44	-	-	-	-	-	-
Total Liabilities	$9.42	$13.11	$13.42	$10.55	$20.53	$17.24	$14.85	$25.34	$15.75	-
Common Stock Net	$0.06	$0.05	$0.05	$0.05	$0.05	$0.04	$0.03	$0300000	$0200000	-
Retained Earnings (Accumulated Deficit)	$-668.84	$-556.26	$-486.79	$-415.80	$-339.41	$-222.04	$0	-	-	-
Comprehensive Income	-	-	$0	$0	$0	$0	$0	-	-	-
Other Share Holders Equity	$0.04	$-0.09	$-0.96	$-0.44	$-0.76	$0.04	-	-	-	-
Share Holder Equity	$109.95	$177.60	$221.81	$276.22	$335.46	$274.64	$98.54	$6.69	$9.69	-
Total Liabilities And Share Holders Equity	$119.38	$190.71	$235.23	$286.77	-	-	-	-	-	-

Annual Data \| Millions of US $ except per share data	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31
Revenue	$12.52	$7.22	$4.49	$5.70	$10.76	$4.04	$4.37	$33.72	$12.10	-
Cost Of Goods Sold	$38.49	$55.24	$49.45	$58.65	$97.72	$61.02	$30.77	$36.22	$36.14	-
Gross Profit	-	-	-	-	-	-	-	-	-	-
Research And Development Expenses	$107.33	$55.24	$49.45	$58.65	$97.19	$45.38	$24.66	$27.82	$27.70	-
SG&A Expenses	$21.17	$23.58	$27.15	$25.01	$31.30	$17.53	$8.33	-	-	-
Other Operating Income Or Expenses	$-12.52	$-7.22	-	-	-	-	-	-	-	-
Operating Expenses	$128.50	$78.82	$76.60	$83.65	$129.01	$62.91	-	-	-	-
Operating Income	$-115.98	$-71.61	$-72.10	$-77.95	$-118.25	$-58.87	$-28.62	-	-	-
Total Non-Operating Income/Expense	-	-	-	-	-	$0.03	$-0400000	-	-	-
Pre-Tax Income	$-112.58	$-69.47	$-70.98	$-76.39	$-117.37	$-59.31	$-29.86	-	-	-
Income Taxes	-	$0	$0	$0	$0	$0	$0	-	-	-
Income After Taxes	-	$0	$0	$0	$0	$0	$0	-	-	-
Other Income	-	-	-	-	-	-	-	-	-	-
Income From Continuous Operations	$-112.58	$-69.47	$-70.98	$-76.39	$-117.37	$-59.31	$-29.86	-	-	-
Income From Discontinued Operations	-	-	-	-	-	-	-	-	-	-
Net Income	$-112.58	$-69.47	$-70.98	$-76.39	$-117.37	$-59.31	$-70.55	-	-	-
EBITDA	-	-	-	-	-	-	-	-	-	-
EBIT	$-115.98	$-71.61	$-72.10	$-77.95	$-118.25	$-58.87	$-28.62	-	-	-
Basic Shares Outstanding	-	-	-	-	-	-	-	-	-	-
Shares Outstanding	$56	$49	$47	$46	$44	$33	$19	$2	$1	$1
Basic EPS	-	-	-	-	-	-	-	-	-	-
EPS - Earnings Per Share	-	-	-	-	-	-	-	-	-	-

Annual Data \| Millions of US $ except per share data	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31
Net Income/Loss	$-112.58	$-69.47	$-70.98	$-76.39	$-117.37	$-59.31	$-36.45	-	-	-
Total Depreciation And Amortization - Cash Flow	$0.56	$0.86	$1.09	$1.06	$0.66	$1.59	$0.70	-	-	-
Change In Accounts Receivable	$-0.90	$1.35	$-0.08	$0.86	$-2.35	$0.14	$0.54	$3.40	-	-
Change In Inventories	-	-	$0	$0	$0	$0	$0	-	-	-
Cash Flow From Operating Activities	$-75.18	$-53.73	$-50.13	$-63.82	$-99.71	$-47.08	$-25.56	-	-	-
Cash Flow From Investing Activities	$10.63	$105.10	$16.43	$94.07	$-169.50	$-159.70	$9.46	-	-	-
Debt Issuance/Retirement Net - Total	-	-	-	-	$-4.35	$-5.70	-	-	-	-
Total Common And Preferred Stock Dividends Paid	-	-	$0	$0	$0	$0	$0	-	-	-
Financial Activities - Other	$-0.02	$-0.40	$-0.05	$-0.05	$-0.34	$-0.34	$-4.95	-	-	-
Cash Flow From Financial Activities	$0.35	$11.19	$0.78	$0.61	$161.35	$225.26	$106.17	$12.31	$42.82	-
Net Cash Flow	$-64.21	$62.56	$-32.92	$30.86	$-107.86	$18.49	$90.07	-	-	-
Common Stock Dividends Paid	-	-	$0	$0	$0	$0	$0	-	-	-